ClinicalTrials.gg
Active, not recruitingNCT05690204Updated Nov 14, 2024

Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.

A Phase 2 interventional study of SAP-001 in Gout, sponsored by Shanton Pharma Pte. Ltd.. Active, not recruiting at 16 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-11-14.

Sponsored by Shanton Pharma Pte. Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 164 studies in Gout with a site in United States — 12 open to participants now, 16 under way, 3 of them phase 3. Gout · United States.

Enrollment
70th of 149
87 · median 74
Started
2022
with 5 others
Phase 2
45 of 164
2 open now
Primary completion
2025-01
later than 1 of 15 live
Registered
139th of 164
by date

Among the 164 studies in Gout with a site in United States, this one is the 70th largest by enrollment of the 149 interventional ones that give a count, is one of 6 that started in 2022, is one of 45 in phase 2, reaches primary completion later than 1 of the 15 other live ones, and was the 139th registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

12 of the 164 studies in Gout with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Gout with a site in United States, or all of them as a file.
02

Study summary

The aim of this study is to confirm the safety and pharmacological characteristics of SAP-001, evaluate its efficacy in lowering sUA and tophus burden, and identify the appropriate dose regimen for future studies in adult subjects with gout, with or without tophi, and hyperuricemia refractory to SoC XOI therapy.

Read the detailed description

A Phase 2B, multicenter, randomized, double-blind, placebo-controlled, dose-finding study to assess the safety, PK, PD, and efficacy of 3 orally administered dosages of SAP-001 compared to placebo QD in adult subjects with gout, with or without tophi, and hyperuricemia refractory to standard-of-care (SoC) XOI therapy. In the completed Phase 1 and Phase 2 studies, SAP-001 was well tolerated at single doses up to 120 mg and at dosages up to 60 mg QD for 28-days in subjects with gout and hyperuricemia and demonstrated statistically significant reductions in sUA levels compared to placebo.

The aim of this study is to confirm the safety and pharmacological characteristics of SAP-001.

03

Conditions studied

  • Gout

Browse trials for

Keywords

  • Hyperuricemia
  • Serum Uric Acid
  • Gout Flare
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. Male or female, ≥18 and ≤75 years of age, willing and able to provide and to adhere to the requirements and guidelines of the protocol.
  2. ≥19 and ≤40 kg/m2 at the Screening Visit (Visit 1).
  3. Already have been diagnosed with gout according to the current American College of Rheumatology (ACR) scoring criteria for the classification of primary gout; or has symptoms of gout with at least 1 of the following: i. 3 gout flares in the previous 18 months prior to screening; or ii. Presence of at least 1 gout tophus; or iii. Current diagnosis of gouty arthritis; Subject must be to SoC XOI therapy, or in whom XOI is . Refractory to SOC XOI is defined by a medical history of failure to normalize sUA to \<6 mg/dL (the ACR target for gout) with at least 3 months of SoC XOI treatment at the maximum medically appropriate dose. XOI contraindication can be self-reported medical contraindication to SoC XOI therapy or in whom SoC XOI therapy is not considered medically appropriate treatment for symptomatic gout. Subject can still participate in the clinical trial if SOC XOI therapy is considered medically not appropriate or contraindicated.
  4. Subject must have been on SoC XOI therapy for gout and hyperuricemia for at least 4 weeks immediately before the Randomization Visit (Day 1, Visit 4) unless SoC XOI therapy is contraindicated or not medically appropriate. Subjects who stopped SoC XOI therapy within 4 weeks of the Screening Visit are eligible for the study but must be restarted on SoC XOI therapy and confirmed resistant to XOI therapy (sUA levels ≥7.0 mg/dL) after at least 4 weeks of treatment.
  5. Subject must have sUA levels ≥7.0 mg/dL by central laboratory results at the Screening Visit (Visit 1) and prior to randomization at the Randomization Visit (Day 1, Visit 4).

Main Exclusion Criteria:

  1. Subjects not previously diagnosed as having gout before the Screening Visit.
  2. Female subject is pregnant, planning to get pregnant, lactating/breastfeeding, or has a positive urine pregnancy test at the Screening Visit or prior to randomization at the Randomization Visit (Day 1, Visit 4).
  3. Subject has used any prescription drugs (eg, losartan, pegloticase, URAT1 inhibitors), OTC medications, herbal medications or products, vitamins, or minerals that are known to lower sUA levels (except SoC XOI therapies) within 14 days prior to the Randomization Visit (Day 1, Visit 4). Exceptions may be made on a case-by-case basis (such as chronic use of low dose aspirin) following discussion and agreement between the investigator and sponsor. Subjects who are already taking losartan for blood-pressure control are allowed to enroll in the study and continue taking losartan if they have been on a stable dose for at least 6 months.
  4. Subject was not compliant with taking placebo during the Run-in Period (defined as taking \<80% or >120% of planned placebo doses) or the investigator determines that the subject was not compliant with SoC XOI gout medications (unless SoC XOI therapy is contraindicated or not medically appropriate) during the Run-in Period as assessed prior to randomization at the Randomization Visit (Day 1, Visit 4).
  5. Subject had an acute gout flare (exclusive of symptomology associated with chronic synovitis/arthritis) that did not resolve at least 14 days prior to the Randomization Visit (Day 1, Visit 4). If an acute gout flare occurs during the Screening or Run-in Periods, the subject may be rescreened after a period of at least 14 days has passed following resolution of the flare.
  6. Serum creatinine level >1.5 mg/dL and/or ≤60 mL/min/1.73 m2 calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation23 by central laboratory results at the Screening Visit (Visit 1) or prior to randomization at the Randomization Visit (Day 1, Visit 4).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    Placebo versus SAP-001

    Placebo arm

    Drug: SAP-001

  • Experimental
    SAP-001 low dose

    SAP-001 low dose

    Drug: SAP-001

  • Experimental
    SAP-001 middle dose

    SAP-001 middle dose

    Drug: SAP-001

  • Experimental
    SAP-001 high dose

    SAP-001 high dose

    Drug: SAP-001

Interventions

  • Test the efficacy and safety of SAP-001 versus placebo

    Also known as: Xanthine Oxidase Inhibitor, Colchicine

06

What researchers measure

Primary outcomes

  1. primary

    assess the proportion of subjects who achieved sUA levels less than 6 mg/dl by laboratory results

    Time frame: 24 weeks

Secondary outcomes

  1. AE

    Incidence of AEs including SAE and TEAEs by CTCAE criteria

    Time frame: 24 weeks

  2. Change from Baseline on PE measure

    Changes from baseline in Physical Exam based on number of participants with abnormal findings

    Time frame: 24 weeks

  3. Changes from Baseline on ECGs

    Changes from baseline in ECG parameters by QTc intervals

    Time frame: 24 weeks

07

Study locations

16 sites
  • California Site
    Sacramento, California 95821, United States
  • California Site
    San Diego, California 92119, United States
  • Denver Site
    Denver, Colorado 80230, United States
  • Florida Site
    DeBary, Florida 32713, United States
  • Florida Site
    Miami Lakes, Florida 33014, United States
  • Florida Site
    Miami Lakes, Florida 33173, United States
  • Florida Site
    Miami, Florida 33173, United States
  • Florida Site
    Winter Park, Florida 32789, United States
  • Idaho Site
    Boise, Idaho 83713, United States
  • Maryland Site
    Oxon Hill, Maryland 20745, United States
  • Mississippi Site
    Jackson, Mississippi 39202, United States
  • North Carolina Site
    Raleigh, North Carolina 27612, United States
  • Texas Site
    Mesquite, Texas 75150, United States
  • Texas Site
    Plano, Texas 75093, United States
  • Texas Site
    The Woodlands, Texas 77832, United States
  • Puerto Rico Site
    San Juan, 00907, Puerto Rico
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Jan 2025, 25 months after the start.

Of 25 industry-sponsored phase 2 interventional studies under Gout, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 19. This study's planned 25 months is above that.

Counting every sponsor, half of 30 studies reached it within 14 months; a quarter within 7 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2022
First posted
Jan 19, 2023
StartActual
Dec 12, 2022
Primary completionEst.
Jan 2025
CompletionEst.
Feb 2025
Last update
Nov 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05690204
Lead sponsor
Shanton Pharma Pte. Ltd.
Responsible party
Sponsor
First posted
Jan 19, 2023
Start date
Dec 12, 2022
Primary completion
Jan 2025 (estimated)
Completion
Feb 2025 (estimated)
Last update
Nov 14, 2024

Study contacts

Carmen Arencibia
study director · Study Official

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SAP-001

Start the discussion